Indalpine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598969

CAS#: 63758-79-2

Description: Indalpine is a selective 5-hydroxytryptamine uptake inhibitor.

Chemical Structure

img
Indalpine
CAS# 63758-79-2
Instruction

Theoretical Analysis

MedKoo Cat#: 598969
Name: Indalpine
CAS#: 63758-79-2
Chemical Formula: C15H20N2
Exact Mass: 228.16
Molecular Weight: 228.330
Elemental Analysis: C, 78.90; H, 8.83; N, 12.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Indalpine; LM 5008; Lipstene; LM-5008; LM5008; Indalpino;

IUPAC/Chemical Name: 3-(2-(piperidin-4-yl)ethyl)-1H-indole

InChi Key: SADQVAVFGNTEOD-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2

SMILES Code: C1(CCC2CCNCC2)=CNC3=C1C=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 228.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Loo H, Benkelfat C, Vanelle JM, Dennis T, Poirier MF, Olie JP, Scatton B. Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression. J Neural Transm. 1986;66(1):47-58. PubMed PMID: 3734775.

2: Seppälä T, Strömberg C, Mattila MJ. Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102. PubMed PMID: 3365283.

3: Naylor GJ, Martin B. A double-blind out-patient trial of indalpine vs mianserin. Br J Psychiatry. 1985 Sep;147:306-9. PubMed PMID: 3904886.

4: Bénavidès J, Savaki HE, Malgouris C, Laplace C, Margelidon C, Daniel M, Courteix J, Uzan A, Guérémy C, Le Fur G. Quantitative autoradiography of [3H]indalpine binding sites in the rat brain: I. Pharmacological characterization. J Neurochem. 1985 Aug;45(2):514-20. PubMed PMID: 3874264.

5: Kafi-De St Hilaire S, Merica H, Gaillard JM. The effects of indalpine--a selective inhibitor of 5-HT uptake--on rat paradoxical sleep. Eur J Pharmacol. 1984 Mar 2;98(3-4):413-8. PubMed PMID: 6233163.

6: Toupin L, Caillé G, Vézina M, Demontigny C, Tawashi M. HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. Biopharm Drug Dispos. 1987 Nov-Dec;8(6):507-17. PubMed PMID: 3427208.

7: Rigal J. [A serotoninergic antidepressive, indalpine]. Ann Med Psychol (Paris). 1985 Jul;143(7):664-76. French. PubMed PMID: 3938629.

8: Blier P, de Montigny C, Tardif D. Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology (Berl). 1984;84(2):242-9. PubMed PMID: 6438684.

9: Savaki H, Malgouris C, Bénavidès J, Laplace C, Uzan A, Guérémy C, Le Fur G. Quantitative autoradiography of [3H]indalpine binding sites in the rat brain: II. Regional distribution. J Neurochem. 1985 Aug;45(2):521-6. PubMed PMID: 4009172.

10: Jozefczak C, Ktorza N, Uzan A. High-performance liquid chromatographic determination of indalpine, a new non-tricyclic antidepressant, in human plasma: identification and simultaneous measurement of its major plasma metabolite. J Chromatogr. 1982 Jun 11;230(1):87-95. PubMed PMID: 7107771.

11: Grosbois B, Milon D, Dauriac C, Leprise PY, Leclech C, Baert A, Beneton C. [Hematologic disorders (acute agranulocytosis) during treatment with indalpine]. Presse Med. 1985 Jan 26;14(3):163-4. French. PubMed PMID: 3156348.

12: Jouvent R, Rodier C, Baruch P, Hardy MC, Lemperiere T, Widlöcher D. Indalpine, a specific 5HT uptake inhibitor, in delusional depression. Psychiatry Res. 1984 Apr;11(4):365-6. PubMed PMID: 6588397.

13: Jaillon P, Cheymol G, Alby JM, Ferreri M, Lecocq B. [Cardiovascular tolerability of indalpine in therapeutic doses]. Therapie. 1986 Jan-Feb;41(1):49-52. French. PubMed PMID: 3704991.

14: Blackett A, Brion N, Turner P. Recovery of acetylsalicylic acid and indalpine (LM 5008) after buccal partitioning. Int J Clin Pharmacol Res. 1983;3(1):5-7. PubMed PMID: 6679508.

15: Brion N, Culig J, Turner P. [Action of indalpine on the pupil diameter in the healthy volunteer]. Therapie. 1985 Jan-Feb;40(1):9-11. French. PubMed PMID: 4002187.

16: Joulin Y, Doare L, Diquet B. Micromethod for the determination of indalpine in mouse plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1986 Sep 5;381(2):457-63. PubMed PMID: 3760103.

17: Laaban JP, Lebras P, Dugay J, Texier F, Vayrac A, Renou P, Ciaudo M, Aimez P, Aubert JP. [3 cases of agranulocytosis during polytherapy including indalpine]. Rev Med Interne. 1985 Oct;6(4):433-5. French. PubMed PMID: 4070852.

18: Uzan A, Kabouche M, Rataud J, Le Fur G. Pharmacological evidence of a possible tryptaminergic regulation of opiate receptors by using indalpine, a selective 5-HT uptake inhibitor. Neuropharmacology. 1980 Nov;19(11):1075-9. PubMed PMID: 6255361.

19: Lôo H, Benkelfat C, Poirier MF, Vanelle JM, Olié JP, Dennis T, Scatton B. Plasma 3,4-dihydroxyphenylethyleneglycol and therapeutic response to maprotiline and indalpine in major depression. Neuropsychobiology. 1986;15(2):62-7. PubMed PMID: 3762900.

20: Arnaud-Castiglioni R, Louvel E, Mesana M, Scotto JC. [Confusional status and simultaneous prescription of amineptin and indalpine. Apropos of 3 recent cases]. Ann Med Psychol (Paris). 1984 Dec;142(10):1331-3. French. PubMed PMID: 6535414.